Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.79 0.13 (0.53%) Market Cap: 3.07 Bil Enterprise Value: 2.91 Bil PE Ratio: 0 PB Ratio: 17.46 GF Score: 53/100

Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2022 / 08:35PM GMT
Release Date Price: €31.29 (+4.23%)
Luca Issi
RBC Capital Markets - Analyst

Great. Thanks. Hello, everybody. Luca Issi, senior biotech analyst here at RBC Capital Markets. And today, it's our great privilege to have Arrowhead Pharma here with us for a fireside chat. Representing the company, we have Vince Anzalone, Head of IR. Vince, thanks again for joining us. How are you doing today?

Vince Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR

Great. Thank you, Luca, and thank you to the whole RBC team for having us today. Great day. Thank you.

Questions & Answers

Luca Issi
RBC Capital Markets - Analyst

Terrific. Terrific. We have a long list of questions here for individual programs, but, maybe before we talk about individual program, can you just maybe give us a high-level overview of Arrowhead, maybe what progress the organization has made in the last few months, and, most importantly, what's ahead?

Vince Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR

Sure. So I think the way I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot